Solventum has appointed former Zimmer Biomet executive Rachel Ellingson as chief strategy and corporate development officer.

Solventum Co. (NYSE:SOLV – Get Free Report) has been assigned an average rating of “Hold” from the eleven brokerages that are currently covering the company, MarketBeat.com reports. One research ...

Mizuho raised the firm’s price target on Solventum (SOLV) to $82 from $70 and keeps a Neutral rating on the shares following the Q4 report. The ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Solventum purification and filtration portfolio expected to be highly complementary with Thermo Fisher’s bioproduction ...

The addition of Solventum’s business provides a strategic fit with Thermo Fisher and will create value for customers, ...

Shares of Solventum Corp. SOLV shed 4.42% to $79.75 Friday, on what proved to be an all-around positive trading session for ...

Solventum stock is down, even though fourth-quarter results that came in ahead of the consensus forecast on Wall Street.

Shares of healthcare solutions provider Solventum (NYSE:SOLV) fell 6.5% in the morning session after the company reported ...

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

Solventum Corp (SOLV) reports robust earnings per share and strategic advancements, while navigating separation complexities and market headwinds.

ST. PAUL, Minn. - Solventum Corporation (NYSE: SOLV) reported fourth-quarter earnings that fell short of analyst expectations, sending shares down 2% in after-hours trading. The healthcare technology ...